Arcato’s Three-Anesthetic Cocktail Shows Safety and Early Analgesic Activity After Wisdom Tooth Surgery

A first-in-human Phase 1 study found ARC-001 Gel safe following third molar extraction, while exploratory analyses indicated reduced postoperative pain during the first 24 hours and a potential duration of analgesia of up to seven days after a single local dose.

Phase 1 Study Meets Primary Safety Endpoint

Arcato Laboratories reported topline results from its Phase 1 study of ARC-001 Gel (NCT06864884) in patients undergoing third molar, or wisdom tooth, extraction. The study met its primary safety endpoint, supporting further clinical development of the investigational local analgesic.

Exploratory efficacy analyses showed a reduction in postoperative pain during the first 24 hours. The company also reported findings suggesting that a single administration could provide pain relief for as long as one week, although these duration findings remain exploratory and will require confirmation in controlled studies.

Patients who received placebo reported needing opioids to manage postoperative pain about twice as often as those treated with ARC-001 Gel.

Sustained-Release Combination of Three Local Anesthetics

ARC-001 Gel combines benzocaine, lidocaine, and bupivacaine in a proprietary sustained-release formulation. All three are established local anesthetics, but the formulation is intended to extend local analgesic exposure following surgical extraction.

The gel is administered directly into the tooth socket after extraction and does not require an injection or needle. Its pharmacokinetic profile is intended to support prolonged local anesthetic activity from a single administration.

This approach addresses a common challenge in oral surgery: maintaining postoperative pain control after the effects of conventional local anesthesia wear off while limiting reliance on systemic analgesics, particularly opioids.

More than 3 million people in the US undergo third molar surgery each year, according to Arcato. Although efforts to reduce opioid prescribing after dental procedures have expanded, postoperative pain management remains an area of clinical need.

Exploratory Efficacy Findings Need Confirmation

The Phase 1 study primarily evaluated safety rather than providing definitive evidence of efficacy. Arcato has not disclosed detailed patient numbers, treatment allocation, numerical pain scores, statistical analyses, or the complete adverse-event profile in the topline announcement.

The reported analgesic findings therefore provide an early clinical signal rather than confirmatory evidence that ARC-001 Gel can sustain pain relief for seven days.

The company intends to use the Phase 1 findings to advance ARC-001 Gel into Phase 2 and Phase 3 development.

Development Moves Toward Later-Stage Trials

Thomas E. Van Dyke, DDS, PhD, Vice President of Clinical and Translational Research at the ADA Forsyth Institute, said the approach could provide an additional local pain-management option following oral surgery, particularly as clinicians continue efforts to reduce postoperative opioid use.

Arcato CEO Jeff Miller said the company is engaged with the FDA and is aligning its development strategy with the agency’s May 2026 draft guidance for non-opioid analgesics.

The company also announced the closing of its first financing round alongside the clinical update. Further clinical development will determine whether the early safety profile and exploratory analgesic signal translate into reproducible, clinically meaningful pain control in larger controlled trials.

 Reference

Arcato Announces Phase 1 Clinical Trial Results and Closing of Fully Subscribed Financing Round